Virachip System Replacement for Lyme Disease Testing

RIPL seeks to replace its existing Virachip system, which is critical for conducting Lyme disease immunoblot testing. As England's frontline reference laboratory for this diagnostic service, RIPL requires a platform that uses multiplex protein microarray technology to assess antibody responses to Borrelia burgdorferi. The system must detect both IgM and IgG antibodies, enabling simultaneous evaluation of multiple Borrelia-specific antigens including VlsE antigen, rather than relying on single-marker detection. This capability supports accurate diagnosis across all stages of Lyme disease infection. Suppliers should note that this is a replacement procurement for an established diagnostic function serving the national reference laboratory network.